Xencor (NASDAQ:XNCR) is a clinical-stage biopharmaceutical company that specializes in the design and development of engineered monoclonal antibodies and Fc-fusion proteins. Utilizing its proprietary XmAb® platform, Xencor creates next-generation biologics aimed at improving efficacy, safety and patient convenience. The company’s research efforts focus primarily on immuno-oncology, autoimmune disorders and inflammation, leveraging advanced antibody engineering to enhance immune system engagement and tissue targeting.
The XmAb platform enables precise control over antibody half-life, effector functions and receptor binding through modifications to the Fc region. Xencor’s product candidates include bispecific antibodies that simultaneously engage two targets, long-acting cytokines designed for reduced dosing frequency and half-life extended antibody therapies. These molecules are engineered to improve therapeutic windows, reduce off-target effects and provide differentiated mechanisms of action compared to conventional biologics.
Xencor has forged strategic collaborations with global pharmaceutical and biotechnology companies to advance its pipeline and accelerate clinical development. Partners include Amgen, Janssen, Pfizer and Alexion, among others, who leverage XmAb technology to enhance their own oncology and autoimmune programs. The company’s pipeline spans multiple clinical and preclinical stages, with leading candidates being evaluated in both monotherapy and combination regimens across solid tumors and hematologic malignancies, as well as chronic inflammatory diseases.
Founded in 1997 and headquartered in Monrovia, California, Xencor was co-founded by CEO David Hallal and a team of experienced scientists. Under Hallal’s leadership, the company has built a robust discovery engine and established a diversified pipeline that reflects decades of expertise in protein engineering. Xencor operates research facilities in the United States, with additional collaborations and developmental activities extending across North America, Europe and Asia.
